-
Mashup Score: 0Treatment with gene-edited cell therapies not associated with subsequent cancer risk - 3 year(s) ago
Patients with cancer who received genetically modified immune effector cells did not demonstrate increased risk for developing subsequent malignancies, according to results of a retrospective study. The analysis — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — yielded no evidence of genotoxicity among patients treated with a variety of
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Long-term follow-up of patients will need to continue as we optimize our immune effector technologies to ensure they don't increase the risk [for] subsequent malignancies in the future," says David Steffin, MD @bcmhouston https://t.co/AnqRf1KWYT #ASGCT21 @davidsteffin
-
-
Mashup Score: 0
UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Expansion and persistence of UCARTCS1A was observed and was found to correlate with clinically meaningful antimyeloma activity and serum cytokine changes in very heavily pretreated patients with multiple myeloma. @ASGCTherapy #ASGCT21 #mmsm https://t.co/SsZc8nD4yj
-
-
Mashup Score: 2Treatment with gene-edited cell therapies not associated with subsequent cancer risk - 3 year(s) ago
Patients with cancer who received genetically modified immune effector cells did not demonstrate increased risk for developing subsequent malignancies, according to results of a retrospective study. The analysis — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — yielded no evidence of genotoxicity among patients treated with a variety of
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEWS from #ASGCT21 - Treatment with gene-edited cell therapies not associated with subsequent cancer risk according to results of a retrospective study https://t.co/IYkvBvP5Zz @bcmhouston @TexasChildrens @MethodistHosp https://t.co/vNLTUgtq10
-
NEWS from #ASGCT21 - Treatment with gene-edited cell therapies not associated with subsequent cancer risk according to results of a retrospective study https://t.co/AnqRf1KWYT @bcmhouston @TexasChildrens @MethodistHosp https://t.co/z3d21fIIM9
-
-
Mashup Score: 5Dr. Larry Corey receives public service award from American Society of Gene & Cell Therapy - 3 year(s) ago
Dr. Larry Corey is one of two winners of the American Society of Gene & Cell Therapy‘s Sonia Skarlatos Public Service Award, which recognizes a person or group that has consistently fostered and enhanced the field of gene and cell therapy.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Congrats Dr. Larry Corey on receiving @ASGCTherapy‘s Sonia Skarlatos Public Service Award at #ASGCT21. Corey is recognized for contributions to the field of gene & cell therapy through his ongoing work with Fred Hutch, @PreventCOVID_19 and @HelpEndHIV. https://t.co/iqLaWhApC9
-
-
Mashup Score: 0CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma - 3 year(s) ago
A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial. The latest data on the investigational agent — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — showed one durable complete
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
CAR-NKT cell therapy shown to infiltrate tumor tissues and induce a complete durable response in patients with advanced neuroblastoma https://t.co/uWj0Rsy9vN #ASGCT21
-
-
Mashup Score: 0CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma - 3 year(s) ago
A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial. The latest data on the investigational agent — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — showed one durable complete
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-NKT cell therapy shown to infiltrate tumor tissues and induce complete durable response in patietns with advanced neuroblastoma https://t.co/IYpP7bo3Af #ASGCT21
-
-
Mashup Score: 0CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma - 3 year(s) ago
A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial. The latest data on the investigational agent — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — showed one durable complete
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma https://t.co/uWj0Rsy9vN #ASGCT21 @AlexsLemonade @CPRITTexas @AmericanCancer @NIH @TexasChildrens @bcmhouston
-
-
Mashup Score: 0CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma - 3 year(s) ago
A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial. The latest data on the investigational agent — presented during the virtual American Society of Gene & Cell Therapy Annual Meeting — showed one durable complete
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-natural killer T-cell therapy shows antitumor activity in advanced neuroblastoma https://t.co/IYpP7bo3Af #ASGCT21 @AlexsLemonade @CPRITTexas @AmericanCancer @NIH @TexasChildrens @bcmhouston
-
-
Mashup Score: 7Dr. Larry Corey receives public service award from American Society of Gene & Cell Therapy - 3 year(s) ago
Dr. Larry Corey is one of two winners of the American Society of Gene & Cell Therapy‘s Sonia Skarlatos Public Service Award, which recognizes a person or group that has consistently fostered and enhanced the field of gene and cell therapy.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Congrats Dr. Larry Corey on receiving @ASGCTherapy‘s Sonia Skarlatos Public Service Award at #ASGCT21. Corey is recognized for contributions to the field of gene & cell therapy through his ongoing work with Fred Hutch, @PreventCOVID_19 and @HelpEndHIV. https://t.co/iqLaWhS0tH
-
-
Mashup Score: 0Cell Press Selection 2021: CRISPR for next-gen therapeutics - 3 year(s) ago
Cell Press Selection 2021: CRISPR for next-gen therapeutics
Source: info.cell.comCategories: General Medicine News, Latest HeadlinesTweet-
Download Cell Press Selections: #CRISPR for next-gen therapeutics. @ASGCTherapy #ASGCT21 https://t.co/Ju8rRdgvYe https://t.co/UNg784Fhb6
-
“Long-term follow-up of patients will need to continue as we optimize our immune effector technologies to ensure they don't increase the risk [for] subsequent malignancies in the future," says David Steffin, MD @bcmhouston https://t.co/IYkvBvP5Zz #ASGCT21 @davidsteffin